ATLANTA — Among a population of patients with hepatitis C that are
typically difficult to treat, sofosbuvir with weight-based ribavirin
demonstrated high efficacy, according to study results presented here.
“Our study population was predominantly African American, most of the
population had the [interleukin]-23 CT/TT genotype with [genotype]-1a
infection, and many also had a high viral load, which are factors that
are associated with difficulty in achieving sustained virologic response
(SVR) with traditional HCV treatment,” Anu Osinusi, MD,
of the National Institute of Allergy and Infectious Diseases, said at
the 2013 Conference on Retroviruses and Opportunistic Infections.